




PHARMACEUTICAL 2023

RespireRx Pharmaceuticals Inc.
Rank 425 of 446





PHARMACEUTICAL 2023

RespireRx Pharmaceuticals Inc.
Rank 425 of 446

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 204% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 203% points.

The company's Economic Capital Ratio, given in the ranking table, is -378%, being 421% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	23
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,729
Liabilities, Non-Current	174
Other Assets	0
Other Compr. Net Income	0
Other Expenses	604
Other Liabilities	0
Other Net Income	80
Other Revenues	0
Property and Equipment	0
Research and Development	430
Selling, General and Administrative Expense	1,150

Output Variable	Value in 1000 USD
Assets	23
Liabilities	11,903
Expenses	2,183
Revenues	0
Stockholders Equity	-11,880
Net Income	-2,103
Comprehensive Net Income	-2,103
Economic Capital Ratio	-378%